Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED).
Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 27, 25 | -0.79 Increased by +18.56% | -0.67 Decreased by -17.91% |
| Nov 8, 24 | -0.49 Increased by +43.68% | -0.80 Increased by +38.75% |
| Aug 14, 24 | -0.86 Decreased by -115.00% | -0.66 Decreased by -29.65% |
| May 14, 24 | -0.36 Increased by +82.94% | -0.98 Increased by +63.27% |
| Mar 28, 24 | -0.97 | -0.99 Increased by +2.02% |
| Nov 7, 23 | -0.87 | -0.50 Decreased by -74.00% |
| Aug 14, 23 | -0.40 | -0.76 Increased by +47.37% |
| Jun 15, 23 | -2.11 | -10.89 Increased by +80.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -79.03 M Increased by +16.99% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -48.55 M Increased by +42.16% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -85.67 M Decreased by -229.01% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -34.97 M Increased by +80.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 166.00 K Increased by +N/A% | -95.21 M Increased by +53.67% | Decreased by -57.36 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -83.94 M Decreased by -482.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -26.04 M Decreased by -79.90% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -176.45 M Decreased by -996.98% | Decreased by N/A% Decreased by N/A% |